Skip to content

US · DRMA · BIOTECHNOLOGY

Dermata Therapeutics, Inc. (DRMA) intrinsic value and stock valuation

$0.51as of 2026-11-21 · Mkt cap 797.42K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dermata Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DRMA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DRMA’s statements →

Dermata Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 dermatarx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-7.56M
20192025
Free cash flow
-$-7.76B
20192025
Total equity
$6.22M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-7.77M-$-12.51M-$-8.04M-$-9.67M-$-7.86M
Net income-$-7.56M-$-12.29M-$-7.79M-$-9.61M-$-7.9M
EPSd-$-8.13M-$-81.93M-$-389.5M-$-137.29M-$-158M
Operating cash flow-$-7.76B-$-11.16M-$-6.41M-$-8.83M-$-5.69M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.76B-$-11.16M-$-6.41M-$-8.83M-$-5.69M
Total assets$7.86M$3.53M$7.98M$6.94M$11.6M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.52M-$-3.16M-$-7.44M-$-6.24M-$-10.8M
Total equity$6.22M$1.56M$6.36M$6.02M$10.1M
Cash and short-term investments$7.52M$3.16M$7.44M$6.24M$10.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.93M$8.2M$4.07M$5.65M$3.46M
Selling, general and administrative expenses$4.84M$4.31M$3.97M$4.02M$4.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$7.77M$12.5M$8.04M$9.67M$7.86M
Cost and expenses$7.77M$12.5M$8.04M$9.67M$7.86M
Interest income$220K$230K$250K$60K$0.00
Interest expense$0.00$0.00$0.00-$-60K$50K
Depreciation and amortization$0.00$0.00$8.04M$0.00$0.00
Ebitda-$-7.77M-$-12.29M$250K-$-9.61M-$-7.86M
Operating income-$-7.77M-$-12.51M-$-8.04M-$-9.67M-$-7.86M
Total other income/expenses, net$220K$230K$250K$60K-$-50K
Income before tax-$-7.56M-$-12.29M-$-7.79M-$-9.61M-$-7.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.56M-$-12.29M-$-7.79M-$-9.61M-$-7.9M
Weighted average shares outstanding$930K$150K$20K$70K$50K
Weighted average diluted shares outstanding$930K$150K$20K$70K$50K
Balance sheet
20252024202320222021
Cash and short-term investments$7.52M$3.16M$7.44M$6.24M$10.8M
Net receivables$0.00$0.00$10K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.86M$3.53M$7.98M$6.94M$11.6M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$0.00
Total assets$7.86M$3.53M$7.98M$6.94M$11.6M
Accounts payable$460K$810K$870K$500K$520K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.64M$1.97M$1.62M$920K$1.52M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00-$0.00-$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.64M$1.97M$1.62M$920K$1.52M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-73.23M-$-65.68M-$-53.39M-$-45.59M-$-35.98M
Accumulated other comprehensive income (loss)$0.00-$0.00$0.00$0.00$0.00
Total equity$6.22M$1.56M$6.36M$6.02M$10.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.52M-$-3.16M-$-7.44M-$-6.24M-$-10.8M
Cash flow statement
20252024202320222021
Net income-$-7.56B-$-12.29M-$-7.79M-$-9.61M-$-7.9M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$143.7M$660K$520K$930K$1.91M
Change in working capital-$-340K$470K$860K-$-150K$290K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-390K-$-110K$370K-$-20K$410K
Net cash provided by operating activities-$-7.76B-$-11.16M-$-6.41M-$-8.83M-$-5.69M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$12.1M$6.89M$7.61M$4.28M$15.4M
Common stock repurchased-$0.00-$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.1B$6.89M$7.61M$4.28M$16M
Net change in cash$4.36B-$-4.28M$1.2M-$-4.56M$10.3M
Cash at end of period$7.52B$3.16M$7.44M$6.24M$10.8M
Operating cash flow-$-7.76B-$-11.16M-$-6.41M-$-8.83M-$-5.69M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.76B-$-11.16M-$-6.41M-$-8.83M-$-5.69M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dermata Therapeutics, Inc.

        Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.

        CEO
        Gerald T. Proehl
        Employees
        9
        Beta
        0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of Dermata Therapeutics, Inc. (DRMA)?

        InvestorsCraft does not currently publish an intrinsic value for DRMA. How the IC value is calculated.

        Is DRMA undervalued?

        InvestorsCraft does not publish an undervaluation signal for DRMA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.